top of page
Product Page: Stores_Product_Widget
Anti-Spike (S-RBD) Rabbit mAb #VYS6

Anti-Spike (S-RBD) Rabbit mAb #VYS6


Rabbit Monoclonal Antibody, Recombinant

  • Product Details

    Aliases of the Protein (Antigen)

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) receptor binding domain (RBD); 2019 novel coronavirus spike glycoprotein RBD, SARS-CoV-2 S1, SARS-CoV-2 S protein RBD; S glycoprotein RBD; S-RBD

    Antigen Background

    UniProt Entry: P0DTC2

    Application Information

    Antigen Molecular Weight: 27 kDa

    Clonality: Rabbit monoclonal antibody

    Clone ID: V700-S2

    Species Reactivity: SARS-CoV-2

    Applications Tested: ELISA

    Antigen Subcellular Location

    Virion; Host ER-Golgi intermediate compartment; host Golgi apparatus; host perinuclear region


    Recombinant SARS-CoV-2 spike receptor binging domain


    Rabbit IgG


    Supplied in PBS (pH 7.5) containing 0.01% sodium azide


    Store at – 20°C

    Recommended Dilutions

    ELISA: 1:10,000

  • Antigen Background

    The single-stranded, plus-sense severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) genome encodes nonstructural replicase polyproteins as well as structural proteins such as spike (S), nucleocapsid (N), membrane (M), and envelop (E) proteins (Zhou et al., 2020). S protein is a transmembrane homotrimeric class I fusion glycoprotein; the S1 subunit binds to angiotensin-converting enzyme II (ACE2) and S2 subunit is involved in the fusion of viral and host cell membranes (Sternberg and Naujokat, 2020). The distal subunit S1 contains a receptor binding domain (RBD, residues Arg319-Phe541, GenBank accession: YP_009724390.1), whose hinge-like conformational movement is required for ACE2 receptor binding and refolding of S2 for membrane fusion (Walls et al., 2020; Wrapp et al., 2020). Accumulating evidence from convalescent COVID-19 individuals supports that RBD is a highly immunogenic epitope targeted by neutralizing monoclonal antibodies through adaptive immune responses mediated by CD4+ T cells (Cao et al., 2020; Grifoni et al., 2020). As such, S and its RBD have been targets for vaccine design and development to prevent SARS-CoV-2 infection and rechallenge (Sternberg and Naujokat, 2020).


    Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell 182, 73-84 e16.

    Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489-1501 e1415.

    Sternberg, A., and Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci 257, 118056.

    Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281-292 e286.

    Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S., and McLellan, J.S. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260-1263.

    Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273.

  • Product Features

    • Recombinant antibodies with minimum batch-to-batch variations
    • Verified with recombinant S-RBD and contrived human nasopharyngeal swab specimens
    • Can be used as a neutralizing antibody for SARS-CoV-2




bottom of page